ClinicalTrials.gg
RecruitingNCT07164976Updated Apr 13, 2026

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

A Phase 1/2 interventional study of Ribociclib 400mg and Ribociclib 600mg in Breast Cancer, sponsored by Nagoya City University. Recruiting at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Nagoya City University · Phase 1/2, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
86
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies testing ribociclib in Breast Neoplasms — 17 open to participants now, 31 under way, 8 of them phase 3. ribociclib · Breast Neoplasms.

Planned enrollment
44th of 70
86 · median 116
Started
2025
with 2 others
Phase 1/2
7 of 70
1 open now
Primary completion
2029-09
later than 20 of 30 live
Registered
64th of 70
by date

Among the 70 studies testing ribociclib in Breast Neoplasms, this one is the 44th largest by planned enrollment, is one of 3 that started in 2025, is one of 7 in phase 1/2, reaches primary completion later than 20 of the 30 other live ones, and was the 64th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 70 studies testing ribociclib in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About ribociclib

ribociclib: first FDA approval 2017 (KISQALI), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing ribociclib in Breast Neoplasms, or all of them as a file.
02

Study summary

This document outlines an investigator-initiated Phase Ib/II clinical trial in Japan, focusing on the combination therapy of ribociclib and anastrozole for patients with hormone receptor-positive (HR-positive), HER2-negative metastatic or recurrent breast cancer. The trial aims to evaluate the efficacy (specifically, overall response rate) and safety of this combination in the Japanese patient population. Nagoya City University is the sponsor of this trial, with funding provided by Novartis Pharma K.K..

Study Design and Endpoints: The trial is structured into two parts:

  • Phase Ib: The primary endpoint for this phase is tolerability, which is assessed by dose-limiting toxicities (DLT). Secondary endpoints include pharmacokinetics (PK) of the drugs, as well as the incidence of adverse events (AE) and serious adverse events (SAE).
  • Phase II: The primary endpoint for Phase II is the Overall Response Rate (ORR), which will be determined by a blinded central imaging review based on RECIST version 1.1 criteria. Secondary endpoints encompass PK (for the initial 20 patients), ORR as assessed by the investigator, progression-free survival (PFS), overall survival (OS), and the overall incidence of adverse events
03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • breast cancer
  • ribociclib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed invasive breast cancer.
  • Hormone receptor-positive (ER positive and/or PgR positive) and -negative disease:

ER positive: ≥1% positive cells or Allred score ≥3.

PgR positive: ≥1% positive cells or Allred score ≥3.

HER2 negative: IHC 0, 1+, or 2+ with no ISH amplification.

  • Advanced or recurrent breast cancer (unresectable, recurrent, or Stage IV).
  • Age ≥18 years at registration.
  • Performance Status of 0-1.

Exclusion criteria

Exclusion Criteria:

  • Symptomatic visceral or deemed unsuitable for endocrine therapy.
  • Prior endocrine therapy or chemotherapy for metastatic/recurrent disease.
  • Prior CDK4/6 inhibitor exposure (perioperative or metastatic setting).
  • endocrine therapy within 35 days before study start.
  • Active other than allowed exceptions (e.g., resected skin cancers, ≥5-year disease-free cancers).
  • to ribociclib, anastrozole, or their components (including soy/peanut allergy, sugar intolerances).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
86 participants (estimated)

Study arms

  • Experimental
    phase 1b cohort 1

    phase 1b cohort 1

    Drug: Ribociclib 400mg

  • Experimental
    phase 1b cohort 2

    phase 1b cohort 2

    Drug: Ribociclib 600mg

  • Experimental
    phase 2 part

    Drug: Ribociclib 600mg

Interventions

This study also gives AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Phase 1b part: Dose Limiting Toxicity

    Time frame: From enrollment to the end of treatment at 4 weeks

  2. Phase 2 part: Overall response rate

    Time frame: From enrollment to the end of treatment at 24 weeks

Secondary outcomes

  1. Phase 1b part: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: From enrollment to the end of treatment at 4 weeks

  2. Phase 1b part: Peak Plasma Concentration (Cmax)

    Time frame: From enrollment to the end of treatment at 4 weeks

  3. Phase 2 part: Overall Response Rate

    Time frame: From enrollment to the end of treatment at 24 weeks

  4. Phase 2 part: PFS

    Time frame: Time Frame: From enrollment to the end of treatment at 24 weeks

  5. Phase 2 part: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: From enrollment to the end of treatment at 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2029, 47 months after the start.

Of 167 non-industry phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 95. This study's planned 47 months is below that.

Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2025
First posted
Sep 10, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Sep 1, 2029
CompletionEst.
Apr 1, 2030
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07164976
Lead sponsor
Nagoya City University
Collaborators
Novartis
Responsible party
Kazuki Nozawa (Principal Investigator, Nagoya City University) — Principal investigator
First posted
Sep 10, 2025
Start date
Oct 1, 2025
Primary completion
Sep 1, 2029 (estimated)
Completion
Apr 1, 2030 (estimated)
Last update
Apr 13, 2026

Study contacts

Kazuki Nozawa
Contact
ribociclib_IIS_CMIC@cmic.co.jp
+81-52-853-8020
Hiroji Iwata, MD. PhD.
study chair · Nagoya City University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribociclib

Start the discussion